CA-125 level as a prognostic indicator in type i and type ii epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 23, Issue 5, 2013, Pages 815-822

  Chen, Xiaoxiang ^a,b,c   Zhang, Jing ^a,b   Cheng, Wenjun ^d   Chang, Doo Young ^a   Huang, Jianfei ^a   Wang, Xuan ^a   Jia, Lizhou ^a   Rosen, Daniel G ^e   Zhang, Wei ^a   Yang, Da ^a   Gershenson, David M ^f   Sood, Anil K ^f   Bast, Robert C ^a   Liu, Jinsong ^a,g  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Southeast University   (China)

^c JIANGSU CANCER HOSPITAL   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f Gynecologic Oncology and Cancer Biology   (United States)

^g FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CYTOREDUCTIVE SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CARCINOMA, TRANSITIONAL CELL; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84880440389     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31828f7a24     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Ozols RF. Recurrent ovarian cancer: Evidence-based treatment. J Clin Oncol. 2002;20:1161-1163.
3. Foster T, Brown TM, Chang J, et al. A review of the current evidence for maintenance therapy in ovarian cancer. Gynecol Oncol. 2009;115:290-301.
4. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82:1535-1538.
5. Zorn KK, Tian C, McGuire WP, et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: A Gynecologic Oncology Group study. Cancer. 2009;115:1028-1035.
6. Mury D, Woelber L, Jung S, et al. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer. J Cancer Res Clin Oncol. 2011;137:1131-1137.
7. Kang S, Kim TJ, Seo SS, et al. Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Gynecol Oncol. 2011;120:18-22.
8. Hogdall E. Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol. 2008;20:4-8.
9. Prat A, Parera M, Peralta S, et al. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol. 2008;19:327-331.
10. Kang S, Kim TJ, Seo SS, et al. Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer. J Gynecol Oncol. 2011;22:269-274.
11. van Altena AM, Kolwijck E, Spanjer MJ, et al. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: A population-based study. Gynecol Oncol. 2010;119:265-269.
12. Kim HS, Park NH, Chung HH, et al. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2008;87:1136-1142.
13. Crawford SM, Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol. 2005;16:47-50.
14. Gard GB, Houghton CR. An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. Gynecol Oncol. 1994;53:283-289.
15. Juretzka MM, Barakat RR, Chi DS, et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol. 2007;104:176-180.
16. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511-1518.
17. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancerVshifting the paradigm. Hum Pathol. 2011;42:918-931.
18. Lu D, Kuhn E, Bristow RE, et al. Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol. 2011;122:560-566.
19. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol. 2010;34:433-443.
20. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol. 2008;61:152-163.
21. McAlpine JN, Porter H, Kobel M, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012;25:740-750.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
23. Prat A, Parera M, Adamo B, et al. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Ann Oncol. 2009;20:294-297.
24. Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23:9338-9343.
25. Wilder JL, Pavlik E, Straughn JM, et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: A preliminary investigation. Gynecol Oncol. 2003;89:233-235.
26. Markman M, Liu PY, Rothenberg ML, et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol. 2006;24:1454-1458.
27. Kang S, Seo SS, Park SY. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer. J Surg Oncol. 2009;100:244-247.
28. Altundag K, Altundag O, Morandi P, et al. CA125 nadir values as a prognostic factor in epithelial ovarian cancer. J Clin Oncol. 2005;23:2435-2436.
29. Paramasivam S, Tripcony L, Crandon A, et al. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: An Australian multicenter study. J Clin Oncol. 2005;23:5938-5942.
30. Markmann S, Gerber B, Briese V. Prognostic value of Ca 125 levels during primary therapy. Anticancer Res. 2007;27:1837-1839.
31. Rubin SC, Hoskins WJ, Hakes TB, et al. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol. 1989;160:667-671.